AlphaRx, Inc. (ALRX.OB) to List Canadian Subsidiary, Expand Chinese Footprint
AlphaRx, Inc., the pharmaceutical developer using a proprietary, site-specific nano delivery technology to reformulate FDA approved drugs to offer significant medical and commercial improvements, announced today plans to list the Company’s China-focused Canadian subsidiary on an exchange in Canada. This move by ALRX will effectively create two public companies, one consisting of developed markets, and one for emerging markets like Asia. With an array of products for multiple pharmaceutical markets, from inflammation to pneumonia and stroke, ALRX is well-positioned to capitalize on this strategic shift to a structure composed of two independent units which will be better able to address…